Thursday, May 26, 2016

BRIEF-Flexion Therapeutics receives positive guidance from FDA on Zilretta NDA

* Flexion Therapeutics receives positive guidance from FDA

on new drug application (NDA) submission for Zilretta for

osteoarthritis of the knee

Source text for Eikon:

Further company coverage:

(Bengaluru Newsroom: +1-646-223-8780)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)